The goal of this observational study is to clarify the clinical characteristics of autoimmune hepatitis (AIH) in China. The main questions it aims to answer are: Human leukocyte antigen (HLA) gene susceptibility in Chinese AIH patients prognostic factors associated with AIH Participants will provide liver tests results and details of treatment during follow-up.
This study aims to establish a high-quality, standardized prospective cohort of AIH with regular follow-up, clarify the clinical characteristics of AIH in China, construct a prognostic model, and explore new serum markers or AIH gene susceptibility, so as to provide key clinical evidence for the prevention and treatment of AIH in China.
Study Type
OBSERVATIONAL
Enrollment
630
Beijing Friendship Hospital, Capital Medical University
Beijing, China
Alanine aminotransferase (ALT) recovery
Normalization of ALT
Time frame: From time of enrollment to the date of first ALT recovery, assessed up to 120 months
Aspartate transaminase (AST) recovery
Normalization of AST
Time frame: From time of enrollment to the date of first AST recovery, assessed up to 120 months
Immunoglobulin G (IgG) recovery
Normalization of IgG
Time frame: From time of enrollment to the date of first IgG recovery, assessed up to 120 months
Death
Patients die because of liver diseases
Time frame: From time of enrollment to the date of death from liver disease, assessed up to 120 months
Liver transplantaiton
Patients have liver transplantation because of AIH
Time frame: From time of enrollment to the date of liver transplantation, assessed up to 120 months
Progression to hepatocellular carcinoma (HCC)
Patients progress to hepatocellular carcinoma due to poor treatment response
Time frame: From time of enrollment to the first date of HCC diagnosed, assessed up to 120 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.